PUBLISHER: Grand View Research | PRODUCT CODE: 1751264
PUBLISHER: Grand View Research | PRODUCT CODE: 1751264
The global DNA nanotechnology market size is expected to reach USD 13.21 billion by 2030 and is anticipated to grow at a CAGR of 19.89% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by rising demand for targeted drug delivery, advanced diagnostics, AI integration in nanostructure design, and increased R&D investments in healthcare and biotechnology sectors.
Furthermore, DNA nanostructures enable precise delivery of therapeutics, reducing side effects and improving treatment outcomes. This precision is especially valuable in oncology, where targeted delivery can minimize damage to healthy cells. In addition, these nanostructures offer programmability and biocompatibility, making them ideal carriers for a wide range of drugs and genetic materials. DNA nanotechnology is crucial in developing patient-specific therapies as personalized medicine gains traction. These innovations are accelerating the adoption of DNA nanostructures in modern drug delivery systems and broader biomedical applications, combined with advancements in AI and nanofabrication.
The COVID-19 pandemic further accelerated the demand for DNA nanotechnology owing to its potential in rapid diagnostics, vaccine development, and targeted drug delivery. DNA-based nanostructures were explored for their ability to detect viral RNA with high sensitivity and support the design of novel therapeutic platforms. The urgent need for advanced biomedical tools during the pandemic highlighted the versatility and scalability of DNA nanotech, driving increased investment and research in the field.
In addition, AI is enhancing the design and efficiency of DNA nanodevices by accelerating structural predictions, optimizing assembly pathways, and improving functional accuracy. Machine learning algorithms enable rapid simulation and analysis, reducing development time and costs. This integration of AI supports the creation of more stable, complex, and application-specific nanostructures, further expanding the potential of DNA nanotechnology in medicine, diagnostics, and nanomaterials.
However, designing and synthesizing DNA nanostructures remains expensive and resource-intensive, which is anticipated to hamper market growth. This is attributed to the need for specialized equipment, skilled expertise, and time-consuming validation processes. These factors increase production costs and limit scalability, posing challenges for widespread adoption. Addressing these limitations will be critical for sustaining long-term market expansion.